AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.…
AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
AbCellera Biologics (NASDAQ: ABCL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 562 employees.
The shares were at 9.690 USD on 20 November 2026, up 144.1% over 52 weeks. Its 52-week range is 2.745 USD to 15.02 USD: the price is 35.5% below the high and 253.0% above the low.
Its market capitalisation is 3.16B USD.
AbCellera Biologics reports return on equity of -15.1%, an operating margin of -298.0% and revenue up 18.8% year over year.
It holds more cash than debt, a net cash position of 630.60M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 18.69 USD is 92.9% above the current price. The next earnings report is expected on 23 February 2027.